HK Stock Market Move | INNOGEN-B(02591) rose more than 17% in early trading, and a positive progress has been made in the management of pet diabetes with Ipragliflozin.

INNOGEN-B (02591) rose more than 17% in the morning session, reaching a 16.11% increase to HK$29.26 at the time of writing, with a turnover of HK$17.2186 million. On the news front, INNOGEN-B announced that on February 4, 2026, the company's core product, Isuprel glucagon peptide alpha, for the treatment of pet diabetes, has had its new veterinary drug clinical trial application formally accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. It is expected to begin Phase I clinical trials in the first quarter of 2026. The board believes that developing drugs for pet diabetes has great potential. As people are increasingly willing to spend money to extend their pets' lives, the board believes that this type of research and development aligns with the group's long-term business development strategy and will establish a solid foundation for the group's future entry into the pet pharmaceutical field. The group has complied with all relevant standards and regulatory requirements for veterinary drug research and registration set by the Ministry of Agriculture, and has successfully completed relevant pre-clinical trials. Based on the results of pre-clinical trials, Isuprel glucagon peptide alpha has made positive progress in managing pet diabetes in terms of efficacy and safety, providing a reasonable basis for future clinical trials and registration applications for the drug.